AVE Science & Technology Co

AVE Science & Technology Co Net Tangible Assets

The Net Tangible Assets of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 514.36 M CNY. In the previous year, Net Tangible Assets was 471.85 M CNY — a change of 9.01% (higher).

Net Tangible Assets

514.36 MCNY

YoY

9.01%

Last updated:

Net Tangible Assets of AVE Science & Technology Co is 2025 514.36 M CNY. Net Tangible Assets of AVE Science & Technology Co was 2024 471.85 M CNY. It decreases by 9.01% higher compared to the previous year.

The AVE Science & Technology Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
195.27 M CNY
Jan 1, 2019
231.01 M CNY
Jan 1, 2020
214.92 M CNY
Jan 1, 2021
456.38 M CNY
Jan 1, 2022
452.71 M CNY
Jan 1, 2023
466.84 M CNY
Jan 1, 2024
471.85 M CNY
Jan 1, 2025
514.36 M CNY
The AVE Science & Technology Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
514.36 MCNY+9.01%
471.85 MCNY+1.07%
466.84 MCNY+3.12%
452.71 MCNY-0.80%
456.38 MCNY+112.35%
214.92 MCNY-6.96%
231.01 MCNY+18.30%
195.27 MCNY+2.80%
189.95 MCNY+6.81%
177.84 MCNY+20.54%
147.53 MCNY+6.69%
138.28 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Net Tangible Assets of AVE Science & Technology Co is 514.36 M CNY in 2025.

Net Tangible Assets of AVE Science & Technology Co changed from 471.85 M CNY to 514.36 M CNY, representing a 9.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's AVE Science & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co